BI 705564 clinical trials
Also written BI 705564.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses BI 705564 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 705564
- 3
Studies by the year they started
4 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BI 705564 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down MidazolamCompletedPhase 1Boehringer IngelheimNCT03325712Written as BI 705564
- Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT03123185Written as BI 705564 (Test)
- This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are ToleratedWithdrawnPhase 1Boehringer IngelheimNCT03747926Written as BI 705564
- BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)WithdrawnPhase 1Boehringer IngelheimNCT03771885Written as BI 705564